Ep113: Lewis Cantley & Siddhartha Mukherjee on Fighting Cancer with Food and Drugs

Episode Summary

Executive Summary: Lewis Cantley and Siddhartha Mukherjee discuss Fayeth Therapeutics’ thesis that carefully monitored nutrition can act as a cancer therapy adjunct by lowering insulin and altering amino-acid availability to starve tumors and improve drug response. They frame diet as a clinically testable, reimbursement-worthy “fifth pillar” of cancer care, and describe ongoing randomized trials combining meal delivery and monitoring with existing drugs.

Main Topics: Origins of the cancer metabolism thesis (Priority: 5/5): Cantley traces the science from his discovery of PI3K and its role in insulin signaling, glucose uptake, and cancer growth, while Mukherjee emphasizes cancer cell physiology as distinct from mutation alone. Insulin as a driver of tumor growth (Priority: 5/5): The guests argue that insulin—not just glucose—is central to fueling tumor anabolic growth, because PI3K mediates insulin’s effects and hyperinsulinemia can support cancer progression. Diet as a therapeutic intervention (Priority: 5/5): They propose structured, monitored insulin-lowering diets, akin to ketogenic diets, to reduce insulin signaling while preserving patient energy via ketones. Precision nutrition paired with drugs (Priority: 5/5): Fayeth’s model combines dietary interventions with specific therapies such as PI3K inhibitors, SGLT2 inhibitors, or chemotherapy to enhance efficacy and potentially shrink tumors. Clinical trial design and compliance (Priority: 4/5): They stress that dietary claims must be tested like drugs: randomized, controlled trials, delivered meals, glucose monitoring, biomarker tracking, and adherence checks. Beyond carbohydrate restriction: amino-acid targeting (Priority: 4/5): The company also explores restricting specific amino acids such as serine, glycine, methionine, and proline, based on preclinical data suggesting synergy with anticancer drugs. Commercial and regulatory pathway (Priority: 4/5): The founders explain that a company is needed to deliver meals at scale, run proper trials, and potentially secure FDA acceptance and insurance reimbursement if efficacy is proven.

Key Arguments: Cancer cells are metabolically distinct and can be targeted by manipulating fuel availability rather than only by attacking mutations directly. Insulin is presented as a key growth signal for tumors; lowering insulin may be more important than simply lowering blood glucose. Ketogenic or insulin-lowering diets can maintain patient physiology through ketones while reducing insulin-driven tumor support. Dietary intervention must be highly controlled and monitored to be scientifically valid, just like a drug trial. Combining diet with PI3K inhibitors may overcome hyperglycemia induced by those drugs and improve cancer response beyond current outcomes. Specific amino-acid restriction offers a second therapeutic axis beyond carbohydrate restriction, potentially tailored to tumor type and drug regimen. The founders believe nutrition should be considered an additional pillar of cancer therapy alongside surgery, radiation, chemotherapy, and immunotherapy.

Data Points: PI3K inhibitor outcome: 6 months progression-free survival - Mukherjee cites approved alpelisib (PI3K inhibitor) in breast cancer as a modest benchmark that Fayeth aims to improve Glucose response vs insulin response: ~5% glucose increase vs 10-30x insulin increase - Cantley explains that sugary or rapid-release carbohydrate meals can cause a much larger insulin spike than glucose rise Tumor glucose uptake: ~50-fold faster - Cantley describes Warburg-effect-like tumor glucose uptake compared with normal tissue Clinical monitoring: Daily reporting + weekly review - Patients log food intake daily and the company reviews reports weekly Biomarker monitoring: Continuous glucose monitoring - Patients wear glucose monitors that transmit data electronically to physicians Trial duration estimate: ~5 years - They say a phase 3-style trial may take up to five years, though they hope to accelerate enrollment Evidence base: 5 foundational papers - Fayeth curated five key papers published in Nature and Science between 2013 and 2019 Founder timeline: 1980s discovery - Cantley references his late-1980s discovery of PI3K as the origin point for the science

Pivotal Quotes: "We think that metabolics and nutrition are a fifth pillar or sixth pillar of cancer therapy." — Lewis Cantley: Describing the company’s broader vision for nutrition as a standard component of oncology care "We know exactly how it works. It's keeping insulin down, and insulin drives the growth of tumors." — Siddhartha Mukherjee: Explaining the mechanistic rationale behind the diet-drug combination strategy "This is a completely different way of thinking about cancer." — Siddhartha Mukherjee: Reflecting on the shift from conventional treatment pillars to diet-based metabolic intervention

Implications: If validated, diet-plus-drug regimens could become reimbursable oncology treatments that improve response, slow progression, and lower costs. The model may reshape cancer care by making nutrition a regulated therapeutic tool, not just lifestyle advice.